Innovent reveals Phase 1 clinical results of Mazdutide for obesity
Category: #health  By Mateen Dalal  Date: 2022-06-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

Innovent reveals Phase 1 clinical results of Mazdutide for obesity

Innovent Biologics, Inc., a biopharmaceutical company that develops, manufacturers, and commercializes top-class medicines, has recently announced the outcomes of high-dose cohorts in Phase 1 clinical study of mazdutide (IBI362), a glucagon receptor dual agonist, and a glucagon-like petide-1 (GLP-1), in adults in China with obesity or overweight at ENDO 2022.

As per credible sources, this placebo-controlled, randomized, double-blind, multiple-ascending-dose study examined the tolerability, safety, and PK/PD features of mazdutide in Chinese participants with obesity or overweight. Each cohort of participants established administration for 12 weeks, except those members in cohort 4 received administration for 16 weeks.

The study's principal investigator, Professor Linong Ji from Peking University People's Hospital, stated that the obese population of China had surpassed 100 million. Most patients cannot achieve weight loss owing to the lifestyle intervention, specifying the urgent requirement for a highly effective and safe weight loss treatment.

The country is pleased to see high-dose mazdutide demonstrating a similar safety profile while showcasing more effective weight loss and several benefits in metabolic parameters.

While commenting on the outcomes, Vice President of Clinical Development of Innovent, Dr. Lei Qian said that the high dose of mazdutide demonstrated satisfactory safety, admissibility, and robust efficacy for weight loss in Chinese patients with obesity or overweight.

Mazdutide is the only molecule to accomplish a 12-week weight loss by around 11.5% among single-agent anti-obesity molecules authorized or under development.

These results showcase the dominance of glucagon receptor dual agonists and GLP-1 around GLP-1 receptor mono-agonists in terms of losing weight.

Moreover, as per the recent reports, the study also authorized the multiple metabolic assistances offered by mazdutide to patients with obesity or overweight. The firm is also planning to continue developing the high-dose mazdutide in obesity and overweight and other potential indications apart from the different exciting results.

Source Credit - https://www.prnewswire.com/news-releases/innovent-releases-results-of-high-dose-cohorts-in-phase-1-clinical-study-of-mazdutide-ibi362-in-chinese-adults-with-overweight-or-obesity-at-endo-2022-301566184.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Microsoft investigates Teams and Outlook outage that left users disrupted
Microsoft investigates Teams and Outlook outage that left users disrupted
By Mateen Dalal

Microsoft, the U.S.-based technology frontrunner, reportedly investigating an outage that prevented thousands of customers from accessing services like Teams and Outlook. Apparently, the tech giant did not disclose the number of users that were im...

DeHaat secures $60 million in funding, tops $700 million valuation
DeHaat secures $60 million in funding, tops $700 million valuation
By Mateen Dalal

Indian agritech firm DeHaat has reportedly raised $60 million in a new funding round as it looks forward to strengthening its footprint in the country and touching break-even profitability in two years. For the unversed, the startup provides a range ...

Sensorium registers new branch in UAE to expand global presence
Sensorium registers new branch in UAE to expand global presence
By Mateen Dalal

Sensorium, developer of the Sensorium Galaxy metaverse, has registered its new branch in the United Arab Emirates (UAE) as Dubai gradually becomes a global hub for metaverse companies. The new entity, slated to be officially inaugurated in the com...